Edition:
United States

Geron Corp (GERN.O)

GERN.O on Nasdaq

2.64USD
26 Jul 2016
Change (% chg)

-- (+0.00%)
Prev Close
$2.64
Open
$2.63
Day's High
$2.69
Day's Low
$2.62
Volume
983,160
Avg. Vol
1,846,003
52-wk High
$5.30
52-wk Low
$2.30

GERN.O

Chart for GERN.O

About

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for... (more)

Overall

Beta: 2.78
Market Cap(Mil.): $419.66
Shares Outstanding(Mil.): 158.96
Dividend: --
Yield (%): --

Financials

  GERN.O Industry Sector
P/E (TTM): 737.43 41.28 37.71
EPS (TTM): -0.00 -- --
ROI: 0.40 -9.20 14.43
ROE: 0.40 -9.24 15.61

BRIEF-Geron announces issuance of U.S. patents related to Imetelstat

* Geron announces issuance of U.S. patents related to Imetelstat

Jul 13 2016

BRIEF-Geron Corp reports Q1 loss per share $0.06

* Geron corporation reports first quarter 2016 financial results and recent events

May 05 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Wright Reports
$75.00
Provider : ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.